This site is intended for healthcare professionals
  • Home
  • /
  • Clinical trials
  • /
  • Uncategorised Disease
  • /
  • Role of the Therapy Tailored to Risk Factors in Tr...
Clinical trial

Role of the Therapy Tailored to Risk Factors in Treating Adult Patients (?60) With Acute Myeloid Leukemia (PALG-AML2012)

Read time: 1 mins
Last updated:24th Feb 2014

In view of the diversity of the biology of acute myeloid leukemia (AML) therapy in individual patients must be individualized. One of the tools for this is molecular-cytogenetic stratification. It divides patients into five categories (prognostic groups): Favorable, Intermediate-1, Intermediate-2, Adverse and Very adverse risk. After remission proceedings are tailored depending on prognostic determined groups.

Research of PALG group in the application in the second line regimen CLAG and CLAG-M proved high effectiveness of this treatment with low toxicity. Considering experience of PALG groups, it seems that the use of the schema CLAG early as the second induction therapy is a viable treatment option.

Category Value
Study start date 2014-02-24

View full details